Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study.

Department of Psychiatry and Psychotherapy, Georg-August-University of Göttingen, Germany.
The Journal of Clinical Psychiatry (Impact Factor: 5.14). 07/2001; 62(6):453-63. DOI: 10.4088/JCP.v62n0609
Source: PubMed

ABSTRACT Over recent years, the use of antidepressants for the symptomatic treatment of insomnia has grown substantially, but controlled studies are still lacking. Our study is the first investigation to prove objective efficacy and tolerability of low doses of a sedating antidepressant in a randomized, double-blind, and placebo-controlled manner in patients with primary insomnia.
Forty-seven drug-free patients meeting DSM-IV criteria for primary insomnia (mean +/- SD duration of complaints = 11.2+/-9.7 years) received either 25-50 mg of the tricyclic antidepressant doxepin or placebo for 4 weeks followed by 2 weeks of placebo withdrawal. Sleep was measured by polysomnography at baseline and the first night of application, at 4 weeks of treatment and the first to third night of withdrawal, and after 2 weeks of withdrawal.
In the doxepin-treated patients who completed the study (N = 20, 47.6+/-11.3), medication significantly increased sleep efficiency after acute (night 1, p < or = .001) and subchronic (night 28, p < or = .05) intake compared with the patients who received placebo (N = 20, 47.4+/-16.8 years of age). Latency to sleep onset was not affected since the patients had normal baseline sleep latencies. Investigators found doxepin to cause significantly (p < or = .05) better global improvement at the first day of treatment. Patients rated sleep quality (p < or = .001) and working ability (p < or = .005) to be significantly improved by doxepin during the whole treatment period. Overall rebound in sleep parameters was not observed, but patients with severe rebound insomnia were significantly more frequent in the doxepin group (night 29, p < .01, night 30, p < or = .01; night 31, p < or = .05). No significant group differences in side effects were found, but 2 doxepin-treated patients dropped out of the study due to specific side effects (increased liver enzymes, leukopenia, and thrombopenia).
The results support the effectiveness of low doses of doxepin to improve sleep and working ability in chronic primary insomniacs, although subjective effects were light to moderate, and in some patients, rebound insomnia and specific side effects have to be considered.

Download full-text


Available from: Dieter Riemann, Jun 29, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners. These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. A consensus meeting was held in London in May 2009. Those invited to attend included BAP members, representative clinicians with a strong interest in sleep disorders and recognized experts and advocates in the field, including a representative from mainland Europe and the USA. Presenters were asked to provide a review of the literature and identification of the standard of evidence in their area, with an emphasis on meta-analyses, systematic reviews and randomized controlled trials where available, plus updates on current clinical practice. Each presentation was followed by discussion, aimed to reach consensus where the evidence and/or clinical experience was considered adequate or otherwise to flag the area as a direction for future research. A draft of the proceedings was then circulated to all participants for comment. Key subsequent publications were added by the writer and speakers at draft stage. All comments were incorporated as far as possible in the final document, which represents the views of all participants although the authors take final responsibility for the document.
    Journal of Psychopharmacology 11/2010; 24(11):1577-601. DOI:10.1177/0269881110379307 · 2.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A meta-analysis assessing the magnitude of sleep changes from baseline in placebo-treated (psychological and pharmacological placebo) and untreated groups issued from independent trials was conducted. Comparisons were then performed to assess if the magnitude of sleep changes in the placebo control groups were significantly different than those of the untreated group. Medline, PsychInfo and Current Contents databases (1990-2004) were searched for primary insomnia treatment studies using a randomized controlled parallel-group design. Effect sizes were computed for each end-point variable based on subjective (patient-reported) and polysomnographic measures. Thirty-four studies (n = 1392 subjects) met inclusion criteria; twenty-three used a pharmacological placebo (n = 1163), four used a psychological placebo (n = 81), and seven used a waitlist condition (n = 148). Between-group comparisons were performed using a random effects model analysis. Significant pre-post changes were observed in the pharmacological placebo condition on several sleep parameters, both on objectively and subjectively measured outcomes [objective and subjective sleep onset latency (SOL) and total sleep time (TST) and subjective wake after sleep onset]. Although a tendency was observed for objective SOL, only the changes on subjective SOL and TST in the pharmacological placebo condition were significantly different from the corresponding changes in the untreated group. No differences were significant for the psychological placebo groups. Although the present findings suggest that sleep may significantly change in response to a pharmacological placebo, conclusions remain tentative because of possible confounds that may arise when comparing groups issued from different trials. Further research directly comparing placebo groups and untreated groups from the same randomized trials remains necessary.
    Journal of Sleep Research 04/2007; 16(1):77-84. DOI:10.1111/j.1365-2869.2007.00566.x · 2.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Question of the study  Previous studies showed that disturbed sleep is a common and frequent complaint reported by tinnitus patients. The purpose of this small pilot study was to investigate the impact of tinnitus as a cause of secondary insomnia.Patients and methods  We compared polysomnographic records of ten patients with presently untreated chronic tinnitus and a complaint of disturbed sleep with those of 20 patients with primary insomnia and 20 age- and gender-matched healthy controls. Psychometric measurements were also performed using a tinnitus-standard rating scale, PSQI, SF-A, and BDI.Results  Concerning subjective sleep quality, both tinnitus and insomnia patients rated their sleep as significantly impaired compared to controls. Differences between patients and healthy controls were also observed with respect to their sleep patterns, with tinnitus patients showing a decreased sleep efficiency (P = 0.049) and total sleep time (P = 0.035) and an increased frequency of awakenings (P = 0.016).Conclusions  The results indicate that tinnitus is associated with subjective and objective sleep disturbances and stress the important impact of sleep disturbances in these patients.ZusammenfassungFragestellung  In früheren Studien wurden Schlafstörungen als generelle und häufige Beschwerden bei Tinnitus genannt. In dieser Pilot-Studie wird die Bedeutung des Tinnitus als Ursache der sekundären Insomnie untersucht.Patienten und Methodik  Es wurden polysomnographische Schlafparameter von 10 Patienten mit chronischem unbehandeltem Tinnitus, die über Schlafstörungen klagten, mit denen von 20 Patienten mit primärer Insomnie und 20 gesunden Probanden verglichen. Psychometrische Befunde wurden durch eine Tinnitus-Beurteilungsskala, SF-A, PSQI und BDI erfasst.Ergebnisse  Hinsichtlich der subjektiven Schlafeinschätzung ergab sich ein signifikant schlechterer Schlaf bei den Tinnitus-Patienten und Insomniepatienten gegenüber den gesunden Probanden. Die polysomnographischen Ableitungen ergaben bei den Tinnitus-Patienten ein schlechteres Schlafprofil im Vergleich zu den gesunden Probanden mit signifikant reduzierter Schlafeffizienz (P = 0,049), reduzierter Schlafzeit (P = 0,035), sowie erhöhtem Anteil an Wachperioden (P = 0,016).Schlussfolgerung  Tinnitus ist assoziiert mit subjektiven und objektiven Schlafstörungen; dies unterstreicht die Bedeutung von Schlafstörungen für das Gesamtbeschwerdebild dieser Patienten.
    Somnologie - Schlafforschung und Schlafmedizin 08/2005; 9(3):133 - 138. DOI:10.1111/j.1439-054X.2005.00056.x